Retroperitoneal fibrosis following a long-standing etanercept treatment in a spondyloarthritis patient

Joint Bone Spine. 2018 May;85(3):389-390. doi: 10.1016/j.jbspin.2017.05.024. Epub 2017 Jul 28.

Authors

Stefania Manganelli¹, Chiara Giannitti², Mauro Galeazzi², Marco Rossi²

Affiliations

¹ Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Viale Bracci n(o)16, 53100 Siena, Italy. Electronic address: stefania.manganelli@tin.it.
² Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Viale Bracci n(o)16, 53100 Siena, Italy.

PMID: 28600212
DOI: 10.1016/j.jbspin.2017.05.024

No abstract available

Keywords: Ankylosing spondylarthritis; Etanercept; Retroperitoneal fibrosis.

Publication types

Case Reports
Letter

MeSH terms

Adult
Disease Progression
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Substitution*
Etanercept / adverse effects*
Etanercept / therapeutic use
Follow-Up Studies
Humans
Long-Term Care
Male
Retroperitoneal Fibrosis / chemically induced*
Retroperitoneal Fibrosis / physiopathology
Severity of Illness Index
Spondylarthritis / diagnosis
Spondylarthritis / drug therapy*
Withholding Treatment

Substances

Etanercept